Polarean Imaging plc has announced an exclusive distribution agreement with DK Healthcare Co., Ltd. for the distribution of its innovative Xenon MRI platform in South Korea. This significant partnership marks Polarean’s second international distribution agreement and aims to enhance the Company’s presence in the Asia-Pacific medical imaging market.
Through this collaboration, Polarean will work closely with DK Healthcare to secure the necessary regulatory approvals ahead of the commercial launch of the Xenon MRI platform in South Korea. The agreement is particularly strategic, as South Korea is recognized as one of the leading markets in medical imaging technology, emphasizing early detection and precision medicine.
Founded in 1986 and headquartered in Seoul, DK Healthcare is a prominent provider of diagnostic radiology systems in Korea. The firm has established a strong reputation by partnering with global medical device manufacturers, delivering cutting-edge imaging solutions along with comprehensive technical, clinical, and maintenance support.
Christopher von Jako, Ph.D., CEO of Polarean, expressed enthusiasm about the partnership, stating, “We are delighted to partner with DK Healthcare, one of South Korea’s most respected medical imaging distributors, to expand access to our Xenon MRI platform.” He emphasized that the country’s focus on early detection makes it an ideal market for growth. This agreement is expected to support Polarean’s strategy of expanding internationally through high-quality regional partners while continuing to promote its technology in the U.S. market.
Joonhyuk Lee, CEO of DK Healthcare, also highlighted the importance of the partnership. He remarked, “We are excited to introduce Polarean’s Xenon MRI technology to Korea’s leading hospitals and imaging centers.” Lee noted that the platform offers clinicians a new dimension in lung function assessment, enabling visualization of ventilation and gas exchange that conventional imaging cannot achieve. He believes this technology will play a crucial role in enhancing respiratory care in South Korea, particularly for patients with conditions such as lung cancer and chronic obstructive pulmonary disease (COPD).
About Polarean, the company specializes in medical imaging technology that revolutionizes pulmonary medicine by providing direct visualization of lung function. It aims to address the significant global unmet medical needs of over 500 million patients suffering from chronic respiratory diseases. Polarean has developed the first and only hyperpolarized Xenon MRI inhaled contrast agent, known as XENOVIEW™, which is FDA-approved in the United States.
The XENOVIEW platform represents a comprehensive drug-device solution, encompassing a proprietary Xenon gas blend, a gas hyperpolarization system, and necessary software and accessories. This advanced technology facilitates fully integrated respiratory imaging operations, leading to improved patient outcomes.
Founded in 2012, Polarean operates from offices in Durham, North Carolina, and London, United Kingdom. The company remains committed to increasing global awareness and access to its XENOVIEW MRI technology platform. For additional information about Polarean and its products, visit their official website at www.polarean.com.
In conclusion, the partnership between Polarean Imaging and DK Healthcare not only strengthens Polarean’s foothold in the vital South Korean market but also opens new avenues for advanced respiratory imaging technology, potentially transforming patient care in the region.
